表紙
市場調查報告書
商品編碼
1014776

封閉設備的全球市場 (2021年∼2028年)

Global Closure devices Market - 2021-2028

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球封閉設備市場主要促進因素,是心臟病發作的風險增加與各種心臟疾病的盛行率上升,技術創新的成果,防止併發症的必要性等。各產品種類中的主動式封閉設備,在各通路中的股血管通路佔大半。各地區中北美各國為最大市場。

本報告提供全球封閉設備的市場相關分析,市場規模趨勢預測,及各產品種類、各通路、各終端用戶、各地區的詳細趨勢,主要的推動及阻礙市場要素,主要企業的簡介等相關調查。

目錄

第1章 封閉設備市場:分析方法、範圍

第2章 封閉設備市場:市場定義和概要

第3章 封閉設備市場:摘要整理

第4章 封閉設備市場:市場動態

  • 對市場的影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 封閉設備市場:產業分析

  • 波特的五力分析
  • 流行病學分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 封閉設備市場:新型冠狀病毒感染疾病 (COVID-19)的分析

  • COVID-19對市場的影響分析
    • "COVID-19前" /過去的市場方案
    • "COVID-19中" /目前市場方案
    • "COVID-19後" /未來市場方案
  • COVID-19流行中的價格趨勢
  • 需求與供給的變動階段
  • 感染擴大時政府對市場的配合措施
  • 各製造公司的策略展開情形
  • 結論

第7章 封閉設備市場:各產品種類

  • 簡介
    • 市場規模的分析及與前一年同期相比成長率 (YoY):各產品種類
    • 市場向心力指數:各產品種類
  • 主動式血管閉合設備
    • 簡介
    • 市場規模 (以金額為準,2018年∼2028年)、與前一年同期相比成長率 (YoY) (2020年∼2028年)
    • 夾為基礎設備
    • 縫合為基礎設備
    • 伽馬反轉錄病毒載體
  • 被動式血管閉合設備
    • 插頭為基礎設備
    • 密封膠/凝膠為基礎設備
    • 壓縮協助設備
  • 外部止血設備

第8章 封閉設備市場:各通路

  • 簡介
    • 市場規模的分析及與前一年同期相比成長率 (YoY):各通路
    • 市場向心力指數:各通路
  • 股骨通路
  • 橈骨通路

第9章 封閉設備市場:各終端用戶

  • 簡介
    • 市場規模的分析及與前一年同期相比成長率 (YoY):各終端用戶
    • 市場向心力指數:各終端用戶
  • 醫院
  • 門診病人手術中心
  • 專門診所

第10章 封閉設備市場:各地區

  • 簡介
    • 市場規模 (以金額為準,2018年∼2028年)、與前一年同期相比成長率 (YoY) (2020年∼2028年):各地區
    • 市場規模和與前一年同期相比成長率 (YoY):各地區
    • 市場向心力指數:各地區
  • 北美
    • 簡介
    • 域內市場固有趨勢
    • 市場規模、與前一年同期相比成長率 (YoY):各產品種類
    • 市場規模、與前一年同期相比成長率 (YoY):各通路
    • 市場規模、與前一年同期相比成長率 (YoY):各終端用戶
    • 市場規模、與前一年同期相比成長率 (YoY):各國
  • 歐洲
  • 南美
  • 亞太地區
  • 中東、非洲

第11章 封閉設備市場:競爭情形

  • 主要趨勢與策略
  • 企業佔有率分析
  • 產品的互相比較
  • 值得注意的企業
  • 有顛覆性技術的企業
  • Start-Ups企業

第12章 封閉設備市場:企業簡介

  • Teleflex medical
    • 企業概要
    • 產品的組合/概要
    • 近幾年趨勢
    • 財務分析:概要
  • Johnson & Johnson Services Inc
  • Pfizer Inc
  • Lupin
  • Siemens
  • Koninklijke Philips NV
  • Medsinglong Co Ltd.
  • Guangzhou Medunion Technologies Co.ltd
  • Guangzhou Maya Medical Equipment.Co.ltd
  • Teva Pharmaceutical Industries Ltd

第13章 關於DataM Intelligence

目錄
Product Code: DMMD3449

Market Overview

The Closure devices market. Size was valued at US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Closure devices have emerged as an effective alternative to traditional mechanical compression for femoral artery closure and are widely used in patients undergoing catheterization via the femoral route. They are inserted at the end of a procedure. The devices available fall into two categories, passive closure devices and active closure devices. Passive vascular closure devices stop the bleeding with the use of material that leads to the formation of blood clots or by way of mechanical compression.

Market Dynamics

The growing risk of heart stroke, along with the increasing population suffering from various vascular diseases, will rise the market growth. Technological innovations and developments will drive the closure devices market in the forecast period.

The growing risk of heart stroke, along with the increasing population suffering from various vascular diseases, will rise the market growth

According to the Centers for Disease Control and Prevention (CDC), approximately every 40 seconds, an American will have a heart attack. Every year, 805,000 Americans have a heart attack, 605,000 of them for the first time. According to WHO, cardiovascular diseases (CVDs) are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. According to the latest worldwide statistics calculated globally, nearly 18.6 million people died of cardiovascular disease in 2019,.Which reflects a 17.1% increase over the past decade.

Approximately 7 million invasive cardiovascular procedures are performed worldwide each year. Because the number of cardiovascular procedures performed via the femoral artery approach continues to increase, effective arterial hemostasis techniques are essential to high-quality patient care. Arteriotomy closure devices (ACDs) are used to decrease vascular complications, reduce the time to hemostasis and ambulation. Subsequently, several generations of passive and active ACDs have been introduced that incorporate suture, collagen plug, nitinol clip, and other mechanisms to achieve hemostasis.

Closure devices are used to close a defect or an opening between the right and left sides of the heart. Some of these congenital disabilities are located in the wall (septum) between the upper chambers (atria) of the heart: Patent Foramen Ovale (PFO) and Atrial Septal Defect (ASD).

The Angio-Seal closure device achieves hemostasis by anchoring a collagen plug to the anterior vessel wall through a sheath delivery system.In recent times a new generation of the Angio-Seal device (Angio-Seal STS Platform™) became available. Angio-Seal STS simplifies the deployment process for the operator; by eliminating the post-placement spring, the procedure is concluded in the cath lab.

Technological innovations and developments will drive the closure devices market in the forecast period.

Closure devices were introduced to reduce access site bleeding complications and reduce the time to hemostasis and ambulation. There are two types of closure devices. Passive devices include clamps for assisted compression and newer technologies, like assisted coagulant patches and sealants. Active devices use sutures, collagen plugs, nitinol clips and other mechanisms to achieve hemostasis.

The FDA granted market approval to Rex Medical's bioresorbable Closer Vascular Sealing System (VSS) to achieve rapid hemostasis of femoral artery catheterizations. The system consists of an insertion sheath, dilator and an implant contained in a delivery system. They use a patch placed against the artery wall and is secured outside the vessel by an attached suture is connected to two bioresorbable spheres. The suture helps to bring the patch and spheres together. The patch, spheres are made of polylactide-co-glycolide acid copolymer and suture is made of polydioxanone. The device components dissolve inside the body after the vessel heals.

The vast majority of large-bore vessel closure is performed by percutaneous suture-based techniques like the Prostar® XL and multiple ProGlide® (Abbott Vascular) vascular closure devices (VCD). Both devices are predominantly inserted using a pre-closure technique.

The MANTA™ VCD (Essential Medical) is a collagen-based closure device. It consists of a poly-lactic co glycolic toggle within the artery, connected to a bovine collagen plug, exterior to the vessel wall.

The use of large-bore closure devices is expected to rise given the growth in TAVI and structural heart procedures, percutaneous left ventricular assist device implantation, and endovascular interventions. Beyond the suture-based VCDs, other designs have now arrived-for instance, following results from the SAFE-MANTA trial, the Manta (Essential Medical), which combines a bioresorbable collagen plug and suture system to seal the puncture site, received FDA approval in February 2019. Manta, as well as the InClosure VCD (InSeal Medical) and PerQseal (Vivasure Medical), all have had CE Mark approval for years in Europe. The use of large-bore arteriotomies is peaking with the expanding market of structural heart interventions and MCS. Indeed, catheter-based techniques, such as EVAR and TAVI, have greatly replaced conventional surgical operations.

The side effects of using these devices will hamper the market

The use of percutaneous vascular closure devices has emerged as an alternative to manual compression in achieving hemostasis safely and timely while reducing time to ambulate and improve patients' comfort. The complications of using percutaneous vascular closure devices include hematoma, local bleeding, arteriovenous fistula formation, pseudoaneurysm and arterial leg ischemia. Management of these complications includes conservative treatment, blood transfusion and occasionally surgical repair.

Suture-based vascular closure devices (VCDs) can, in real-world practice, lead to complications and even death, analysis of a US Food and Drug Administration database confirms. These adverse outcomes varied by whether the VCD in question was the decades-old Prostar XL or the newer Perclose ProGlide (Abbott), which arrived on the US market in 2018. Particularly in high-risk patients, it's essential to choose a device that's easier to use and thus, in theory, would be less prone to complications, according to Case and colleagues.

Most VCDs are approved for arteriotomies between 5 and 8 F, with one device approved for up to 21 F. Major complications include infection and limb ischemia.

Segment Analysis

Active closure device will dominate the market in the forecast period

Active vascular closure devices use a variety of methods to directly close the entry site in the artery. For example, these devices include collagen-based and suture-based products or clips. These effectively close the access site but often require a part of the device to remain in the artery, which can cause complications. New devices use materials, such as polyethylene glycol, that dissolve after a short period of time. These are applied to the outside of the artery only and so are considered a more gentle option.

Active VCDs are categorized as suture devices, collagen plug devices or clips. The collagen plug Mynx device was investigated prospectively in 190 patients (50% interventional, 94% 6 Fr) and retrospectively in 238 patients (100% diagnostic and 6 Fr). Device success was achieved in 91-93%. Clip device the Starclose device (Abbott Vascular, Redwood City, Calif.) achieves hemostasis with a 4 mm nitinol clip implant.

Perclose (Abbott Vascular) offers suture-mediated VCDs that have evolved from the Prostar to the Techstar to the Closer, to the Perclose A-T, to the ProGlide. The success of the Perclose devices is 91-94%.The experience of 46 patients of both Techstar and MC, 76% of them stated they would prefer Techstar, and 17% would prefer MC (p < 0.001).47. A cost analysis suggested that Techstar compared with MC reduced post-PCI costs by 13% by facilitating earlier discharge.

The femoral segment dominated the closure devices market

Femoral vascular closure devices are acting as powerful tools for interventional cardiologists and proceduralists to achieve hemostasis at the catheterization entry site. One of the main arteries of the lower limb is the femoral artery and it is one of the most common access site to perform a cardiac catheterization. The common femoral artery is an extension of the external iliac artery (a terminal branch of the abdominal aorta). The indication of using a femoral vascular closure device is to achieve hemostasis through successful closure of the femoral artery puncture site and to decrease the time to attaining successful hemostasis. Hemostasis for large bore access sites for structural interventions is routinely achieved using femoral vascular closure devices.

The hospital segment will dominate the market in the forecast period

High adoption of advanced devices providing enhanced cardiac care.Growing admissions with heart stroke and safety and effectiveness of vascular closure devices in prevention of access site complications in acute stroke patient receiving intravenous (IV) or intra-arterial (IA) IV tissue plasminogen activator. Patience preference for well-equipped emergency cardiac will increase the segment growth.

According to the CDC Percent of visits to emergency departments with coronary artery disease, ischemic heart disease, or history of myocardial infarction indicated on the medical record: 7.2%. During the first lockdown, which began in March 2020, daily hospitalizations for heart failure and AMI declined by 54%. The rates began to increase during April and almost returned to baseline by June. A total of 17 417 emergency hospital admissions (10 215 for heart failure, 7202 for cardiac arrhythmias) and 1832 interventions (749 ablations, 1083 implants) were included.

Geographical Analysis

North America will dominate the closure devices market

Availability of technologically advanced medical facilities, rising incidences of cardiovascular diseases and use of closure devices will rise the market in this region. Technological advances and increased hospital admissions for cardiac problems. The presence of most of the key players in this region is one more factor that will drive its market growth. According to the Centers for Disease Control and Prevention, more than 454,000 hospitalizations related to atrial fibrillation for primary diagnosis are reported each year in the U.S.

Essential Medical Inc. is a privately held medical device company aiming to develop and commercialize new vascular closure devices for femoral punctures after diagnostic and interventional cardiac catheterization procedures. It received U.S. Food and Drug Administration (FDA) clearance for its large bore Manta Vascular Closure Device.

Competitive Landscape

Closure Devices market key players are Intuitive Surgical, Inc, Johnson & Johnson Services Inc, Pfizer Inc, Lupin, Siemens, Koninklijke Philips NV, Intuitive Surgical, Inc, Cook, Medtronic, Teva Pharmaceutical Industries Ltd, Medsinglong Co Ltd., Guangzhou Medunion Technologies Co.ltd and Guangzhou Maya Medical Equipment.Co.ltd.

Closure devices Market Companies to Watch

Teleflex medical

  • Overview: Teleflex is a global provider of designed medical technologies to improve the health and quality of people's lives. They apply purpose-driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Teleflex employees worldwide and are united in the understanding that what we do every day makes a difference. Headquartered in Wayne, PA, Teleflex employs over 14,000 people worldwide and serves healthcare providers in more than 150 countries.
  • Product Portfolio: Company's portfolio is diverse, with solutions in vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Innovative Solutions in healthcare technology.
  • Key Development: On February 5, 2019, Teleflex Incorporated announced its Manta vascular closure device had received FDA premarket approval (PMA). The Manta device is the first commercially available biomechanical vascular closure device designed specifically for large-bore femoral arterial access site closure.

Why Purchase the Report?

  • Visualize the composition of the closure devices market segmentation By Product Type, By Access and End-user highlighting the key commercial assets and players.
  • Identify commercial opportunities in Closure devices Market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Closure devices Market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The closure devices market report would provide an access to an approx. 60 market data table, 50 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Closure devices Market- By Product Type

  • Active Vascular Closure Devices
    • Clip-Based Devices
    • Suture-Based Devices
    • Gamma-Retroviral Vectors
  • Passive Vascular Closure Devices
    • Plug-Based Devices
    • Sealant or Gel-Based Devices
    • Compression Assist Devices
  • External Haemostatic Devices

Closure devices Market-By Access

  • Femoral Access
  • Radial Access

Closure devices Market-By End User

  • Hospitals
  • Specialty clinics
  • Ambulatory surgical centers

Closure devices Market-By Region

  • North America
  • Europe
  • South America
  • Asia Pacific
  • Middle East and Africa

Table of Contents

1. Closure devices Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Closure devices Market- Market Definition and Overview

3. Closure devices Market- Executive Summary

  • 3.1. Market Snippet By Product Type
  • 3.2. Market Snippet By Access
  • 3.3. Market Snippet by End User

4. Closure devices Market- Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The growing risk of heart stroke, along with the increasing population suffering from various vascular diseases, will rise the market growth
      • 4.1.1.2. Technological innovations and developments will drive the closure devices market in the forecast period.
    • 4.1.2. Restraints:
      • 4.1.2.1. The side effects of using these devices will hamper the market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Closure devices Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Closure devices Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Closure devices Market- By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Active Vascular Closure Devices*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    • 7.2.3. Clip-Based Devices
    • 7.2.4. Suture-Based Devices
    • 7.2.5. Gamma-Retroviral Vectors
  • 7.3. Passive Vascular Closure Devices
    • 7.3.1. Plug-Based Devices
    • 7.3.2. Sealant or Gel-Based Devices
    • 7.3.3. Compression Assist Devices
  • 7.4. External Haemostatic Devices

8. Closure devices Market-By Access

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Access
    • 8.1.2. Market Attractiveness Index, By Access
  • 8.2. Femoral Access*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Radial Access

9. Closure devices Market - By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Ambulatory surgical centers
  • 9.4. Specialty Clinics

10. Closure devices Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Access
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Access
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Access
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Access
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Access
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Closure devices Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch
  • 11.5. List of Company with disruptive technology
  • 11.6. List of Start Up Companies

12. Closure devices Market- Company Profiles

  • 12.1. Teleflex medical*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Johnson & Johnson Services Inc
  • 12.3. Pfizer Inc
  • 12.4. Lupin
  • 12.5. Siemens
  • 12.6. Koninklijke Philips NV
  • 12.7. Medsinglong Co Ltd.
  • 12.8. Guangzhou Medunion Technologies Co.ltd
  • 12.9. Guangzhou Maya Medical Equipment.Co.ltd
  • 12.10. Teva Pharmaceutical Industries Ltd

LIST NOT EXHAUSTIVE

13. Closure devices Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us